The impact of preoperative imaging strategies in EGFR-mutant non-small cell lung cancer: a multicenter retrospective review
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
The ADAURA trial demonstrated an overall survival benefit with adjuvant osimertinib in epidermal growth factor receptor-mutant (EGFR-mut) non-small cell lung cancer (NSCLC). As only 50% of patients underwent a preoperative brain MRI scan and PET-CT rates were not reported, concerns were raised that suboptimal staging could have led to the inclusion of patients with metastatic disease. There is, however, limited data on the real-world rates and impact of preoperative PET-CT and brain MRIs in patients with EGFR-mut NSCLC. We sought to characterize preoperative imaging rates and their impact on staging.
Patients and Methods
We retrospectively analyzed patients with EGFR-mut NSCLC who were evaluated for surgery at 3 academic New York hospitals from 2016-2021.
Results
Between 2016 and 2021,109 patients with EGFR-mut NSCLC underwent preoperative evaluation. Of these patients, 107 underwent a PET-CT and 15 (14%) were found to have stage IV disease. Sites of metastatic disease were bone (11), pleura (2), liver (1), and intrapulmonary (1). Thirty-nine patients had stage II or III disease; of those, 23 underwent a brain MRI, which revealed brain metastases in 3 patients. In total, the use of PET-CT and brain MRIs for patients evaluated for surgery upstaged 17% (18/109) of patients to metastatic disease and resulted in 83% (90/109) of patients undergoing surgery.
Conclusions
The use of preoperative PET-CT and brain MRIs led to the detection of metastatic disease in 17% of patients with EGFR-mut NSCLC. These findings underscore the critical role of comprehensive preoperative imaging for clinical practice and clinical trials.
